Remdesivir

Inquiry

Cat Number

API1809249373

CAS Number

1809249-37-3

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

1809249-37-3

EINECS

210-629-4

Storage

-20℃

Synonyms

Veklury;remdesivirum

Molecular Formula

C27H35N6O8P

Molecular Weight

602.58

Smiles

CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4

Appearance

White crystalline solid

Relative Density

1.47±0.1

General Description

Remdesivir is a broad-spectrum antiviral prodrug. Initially considered a potential treatment for Ebola, research has shown it is active against arenaviruses, flaviviruses, filoviruses, paramyxoviruses, pneumoviruses, and coronaviruses. Remdesivir has been identified as a non-obligate chain terminator of RdRp in SARS-CoV-2 as well as related SARS-CoV and MERS-CoV. It has been studied in multiple COVID-19 clinical trials and is now fully approved by the FDA for the treatment of COVID-19.

Mechanism of Action

Remdesivir is a prodrug of an adenosine nucleotide analog. After being distributed into host cells, remdesivir is metabolized by carboxylesterase 1 and/or cathepsin A to form a nucleoside monophosphate intermediate. This intermediate is subsequently phosphorylated by cellular kinases to produce GS-443902, the pharmacologically active nucleoside triphosphate metabolite. As an analog of adenosine triphosphate (ATP), remdesivir triphosphate is preferentially selected by the SARS-CoV-2 RNA-dependent RNA polymerase (also known as Nsp12) over the natural ATP substrate and incorporated into the growing viral RNA chain. Once remdesivir triphosphate is incorporated and the viral RNA template contains it, further RNA synthesis is inhibited.

Application

Remdesivir is a broad-spectrum antiviral medication. Its current primary application is in the treatment of COVID-19, mainly targeting hospitalized patients with the novel coronavirus pneumonia.

Remdesivir is a phosphoramidate prodrug. This modification is used to increase cellular uptake. Remdesivir requires multiple enzyme conversions before it becomes an active drug. This mechanism of action is crucial to antiviral activity against RNA viruses. Remdesivir is first converted to an alanine metabolite by cellular esterase. The alanine metabolite is then activated through phosphoramidation into a nucleoside monophosphate molecule. Cellular enzymes can further phosphorylate this molecule into its final form, the NTP. The NTP competes with ATP for access to the active site of RdRp. Once attached to the growing RNA chain it prevents the extension of the chain. Remdesivir can also be converted into its parent nucleoside analog GS-441524, which permeates into cells and is phosphorylated directly into the active NTP form.

Fig. 1 Illustrative diagram representing RDV intracellular activation. (Taha MS.; et al. 2025)